Patrick

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

No current examples available.

Conflicts of Interest

No current examples available.

Contradictions

No current examples available.

Deceptions

No current examples available.

Recent Articles

Moderna Defies Expectations with Strong Q1 Financials and EU Vaccine Deal, Despite Stock Slump

Moderna Defies Expectations with Strong Q1 Financials and EU Vaccine Deal, Despite Stock Slump

Broke On: Thursday, 02 May 2024 Moderna reports Q1 financial results with lower-than-expected loss per share and surpassing sales expectations, thanks to strong Covid vaccine sales. The EU plans to purchase up to 36 million doses annually for four years. Moderna is preparing launches for its RSV vaccine and Spikevax 2024-2025 formula, with potential FDA approval for the RSV vaccine later this quarter.
Eli Lilly Reports Strong Fourth-Quarter 2023 Financial Results with Revenue Increasing by 28% and FDA Approval of New Products

Eli Lilly Reports Strong Fourth-Quarter 2023 Financial Results with Revenue Increasing by 28% and FDA Approval of New Products

Broke On: Tuesday, 06 February 2024 Eli Lilly reported strong Q4 2023 financial results with revenue increasing by 28%. New Products revenue grew by $1.7 billion to $4.96 billion, led by Mounjaro and Zepbound. Growth Products revenue increased by 5% to $10.53 billion in Q4 2023, led by Verzenio and Jardiance.